Application of multivariate statistical analysis and network pharmacology to explore the mechanism of Danggui Liuhuang Tang in treating perimenopausal syndrome

Xue, Beibei; Chen, Xiaopeng; Wang, Xiaoli; Li, Chunxia; Liu, Jing; He, Qiaoyu; Liu, Erwei

doi:10.1016/j.jep.2021.114543

Cited by 6 publications

(3 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, extensive proof indicates that ovarian pathology variation is closely associated with abnormal PI3K/Akt signaling pathway expression [42]. Advances in the knowledge of the PI3K/Akt pathway have yet to be applied to studies investigating PS, which is characterized by a decline in ovarian function [43]. In the current study, GNS treatment effectively ameliorated PS, adding to the few studies that have demonstrated the therapeutic effect of TCM on PS.…”

Section: Discussionmentioning

confidence: 74%

Biomarkers based on multiplatform comprehensive analysis: A systematic analysis of Geng‐Nian‐Shu in perimenopausal syndrome

Zhang

et al. 2023

J of Separation Science

View full text Add to dashboard Cite

Although Geng-Nian-Shu has been shown to be clinically effective in perimenopausal syndrome, its active components and mechanism have not yet been elucidated. To demonstrate the mechanism-based biomarkers of Geng-Nian-Shu in treating perimenopausal syndrome, a total of 135 chemical constituents including 52 prototype blood constituents were identified via high-performance liquid chromatography-quadrupole-time of flight/mass spectrometry. Then, network pharmacology showed significant enrichment for the PhosphoInositide-3 Kinase/Akt pathway, suggesting that it may be the main regulatory pathway for the Geng-Nian-Shu treatment of the perimenopausal syndrome. Subsequently, multivariate analysis was performed between the Geng-Nian-Shu sham-treated and Geng-Nian-Shu ovariectomy-treated groups and further screened out 18 prototype blood constituents by correlation analysis with plasma estrogen levels to identify potential biomarkers associated with Geng-Nian-Shu treat the ovariectomy-induced perimenopausal syndrome. Finally, the results of pharmacological experimental verification and Pearson correlation analysis indicated that catalpol, ligustilide, paeoniflorin, and gallic acid were selected as biomarkers of Geng-Nian-Shu which were strongly and positively correlated with PhosphoInositide-3 Kinase/Akt signaling pathway. In this study, based on highperformance liquid chromatography-quadrupole-time of flight/mass spectrometry combined with pharmacodynamics, network pharmacology, pharmacology, and other disciplines, we explored the effects and mechanisms of Geng-Nian-Shu in the treatment of perimenopausal syndrome at multiple levels. Using multiplatform technology to investigate the role of Geng-Nian-Shu represents a new strategy for the selection and verification of biomarkers of Geng-Nian-Shu and provides a basis for further development and utilization of Geng-Nian-Shu.

show abstract

Section: Discussionmentioning

confidence: 74%

Biomarkers based on multiplatform comprehensive analysis: A systematic analysis of Geng‐Nian‐Shu in perimenopausal syndrome

Zhang

et al. 2023

J of Separation Science

View full text Add to dashboard Cite

show abstract

“…Contemporary research has further validated the crucial role of CHM in treating a variety of gynecological diseases, including OEC. For instance, studies have shown CHM’s ability to induce apoptosis in ovarian cancer cells through multiple signaling pathways ( Wang et al, 2024 ), ameliorate perimenopausal syndrome by regulating hormones secreted by the ovaries ( Xue et al, 2022 ), and exhibit potential therapeutic effects on pregnancy-related diseases, such as recurrent spontaneous abortion, pre-eclampsia, and gestational diabetes ( Fang et al, 2023 ). Furthermore, a meta-analysis demonstrated that CHM significantly alleviates pain associated with endometriosis with fewer side effects compared to conventional therapies ( Lin et al, 2023 ).…”

Section: Introductionmentioning

confidence: 99%

Exploring the role of Chinese herbal medicine in the long-term management of postoperative ovarian endometriotic cysts: a systematic review and meta-analysis

Ding,

Liu,

Liu

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

BackgroundOvarian endometriotic cysts (OEC) represent the primary manifestation of endometriosis, constituting a hormonally dependent inflammatory disorder in gynecology. It significantly affects the quality of life and reproductive health of women. It is worth noting that traditional Chinese medicine (TCM), especially Chinese herbal medicine (CHM), has been widely applied in mainland China due to its unique therapeutic system and commendable clinical efficacy, bringing new hope for preventing and managing OEC.ObjectiveThis study aims to evaluate the efficacy and safety of CHM in the management of postoperative OEC. Simultaneously, it seeks to explore the medication laws, therapeutic principles, and specific treatment mechanisms of CHM.MethodsEight electronic databases were searched from their inception to 01 November 2023. Randomized controlled trials (RCTs) assessing the therapeutic effects and safety of CHM for postoperative OEC were included. The risk of bias for each trial was assessed using the Cochrane Collaboration’s tool. The certainty of the evidence was evaluated using the GRADE profiler 3.2. Additionally, we extracted formulation from the included studies, conducting a thorough analysis.Results(ⅰ) Twenty-two RCTs involving 1938 patients were included. In terms of the primary efficacy outcome, the CHM group demonstrated a potentially lower recurrence rate compared to both control (odds ratio (OR) = 0.25; 95% confidence intervals (CI): 0.10–0.64) and conventional western medicine (CWM) (OR = 0.26; 95% CI: 0.11–0.65) groups. Furthermore, the joint application of CHM and CWM resulted in a significant reduction in the recurrence rate (OR = 0.26; 95% CI: 0.17–0.40). (ⅱ) Regarding secondary efficacy outcomes, (a) Total clinical efficacy rate: CHM showcased an augmentation in clinical effectiveness compared to both the control (OR = 4.23; 95% CI: 1.12–15.99) and CWM (OR = 2.94; 95% CI: 1.34–6.43) groups. The combined administration of CHM and CWM substantially enhanced overall clinical effectiveness (OR = 3.44; 95% CI: 2.37–5.00). (b) VAS Score: CHM exhibited the capacity to diminish the VAS score in comparison to surgery alone (Mean difference (MD) = −0.86; 95% CI: -1.01 to −0.71). Nevertheless, no substantial advantage was observed compared to CWM alone (MD = −0.16; 95% CI: -0.49 to 0.17). The integration of CHM with CWM effectively ameliorated pain symptoms (MD = −0.87; 95% CI: -1.10 to −0.65). (c) Serum Level of Cancer antigen 125 (CA125): the CHM group potentially exhibited lower CA125 levels in comparison to CWM alone (MD = −11.08; 95% CI: -21.75 to −0.42). The combined intervention of CHM and CWM significantly decreased CA125 levels (MD = −5.31; 95% CI: -7.27 to −3.36). (d) Pregnancy Rate: CHM exhibited superiority in enhancing the pregnancy rate compared to surgery (OR = 3.95; 95% CI: 1.60–9.74) or CWM alone (OR = 3.31; 95% CI: 1.40–7.83). The combined utilization of CHM and CWM demonstrated the potential to enhance pregnancy rates compared to CWM (OR = 2.99; 95% CI: 1.28–6.98). Concerning safety outcome indicators, CHM effectively decreased the overall incidence of adverse events and, to a certain extent, alleviated perimenopausal symptoms as well as liver function impairment. (ⅲ) Most of CHMs were originated from classical Chinese herbal formulas. Prunus persica (L.) Batsch (Taoren), Angelica sinensis (Oliv.) Diels (Danggui), Salvia miltiorrhiza Bunge (Danshen), Paeonia lactiflora Pall. (Chishao), and Corydalis yanhusuo W.T.Wang (Yanhusuo) were most frequently used CHM.ConclusionCHM may be a viable choice in the long-term management of postoperative OEC, with the potential to enhance clinical efficacy while decreasing recurrence and adverse effects.

show abstract

“…Contemporary research has further validated the crucial role of CHM in treating a variety of gynecological diseases, including OEC. For instance, studies have shown CHM's ability to induce apoptosis in ovarian cancer cells through multiple signaling pathways (Wang et al, 2024), ameliorate perimenopausal syndrome by regulating hormones secreted by the ovaries (Xue et al, 2022), and exhibit potential therapeutic effects on pregnancy-related diseases, such as recurrent spontaneous abortion, pre-eclampsia, and gestational diabetes (Fang et al, 2023). Furthermore, a meta-analysis demonstrated that CHM significantly alleviates pain associated with endometriosis with fewer side effects compared to conventional therapies (Lin et al, 2023).…”

Section: Introductionmentioning

confidence: 99%

Table1.docx

View full text Add to dashboard Cite

Application of multivariate statistical analysis and network pharmacology to explore the mechanism of Danggui Liuhuang Tang in treating perimenopausal syndrome

Cited by 6 publications

References 26 publications

Biomarkers based on multiplatform comprehensive analysis: A systematic analysis of Geng‐Nian‐Shu in perimenopausal syndrome

Biomarkers based on multiplatform comprehensive analysis: A systematic analysis of Geng‐Nian‐Shu in perimenopausal syndrome

Exploring the role of Chinese herbal medicine in the long-term management of postoperative ovarian endometriotic cysts: a systematic review and meta-analysis

Table1.docx

Contact Info

Product

Resources

About